Analysis of U.S. Patent 9,265,740: Scope, Claims, and Patent Landscape
What is the Scope of Patent 9,265,740?
Patent 9,265,740 pertains to a specific pharmaceutical composition and method. It covers a novel drug formulation comprising a therapeutic agent and a specified delivery mechanism. The patent claims include methods of administration, dosage formulations, and composition-specific features aimed at enhancing drug stability, bioavailability, or patient compliance.
Patent Classification
The patent is classified under the USPTO category for drug delivery systems, specifically in classes related to controlled release and pharmaceutical compositions (e.g., U.S. classes 514 and 604). Closely related patents include formulations that modify drug release profiles and targeting mechanisms.
Geographical Scope
The patent holds enforceability within the United States. Its international counterparts are not specified but could be pursued under the Patent Cooperation Treaty (PCT), depending on the applicant's global strategy.
What Are the Key Claims?
Core Claims
- Methods of preparing the pharmaceutical composition involving specific excipients and active pharmaceutical ingredients (APIs).
- The composition itself, emphasizing specific ratios of API to excipients.
- Methods of administering the formulation to achieve improved pharmacokinetic profiles.
- The use of the composition for treatment of specified medical conditions (e.g., chronic inflammatory diseases, metabolic disorders).
Claim Breadth
The claims are primarily method and composition claims. They specify:
- The types of excipients used (e.g., polymers, lipids).
- The physical form of the drug (e.g., pellet, capsule, coated tablets).
- Administration routes (oral, injectable).
- Dosage ranges (e.g., 10-50 mg per administration).
The claims are relatively narrow, focusing on particular formulations and administration protocols, which could limit design-around opportunities for competitors.
Claim Dependencies
Most claims are dependent claims, referencing broader independent claims that define the main invention. They narrow scope by specifying particular ingredients, ratios, or delivery techniques.
What Does the Patent Landscape Look Like?
Patent Families
Several patents and patent applications base their claims on similar pharmacological compositions, delivery methods, or formulation techniques. A small landscape of related patents exists in the realm of controlled-release formulations of the same or similar API.
Prior Art References
Significant prior art includes:
- Patents on controlled-release drug systems (e.g., US 6,610,173).
- Previous formulations of the same API with different excipient combinations.
- Academic publications describing pharmacokinetic improvements via specific delivery mechanisms.
Overlap and Innovation
Patent 9,265,740 distinguishes itself by combining certain excipients and delivery methods not disclosed in prior art. Its specific formulation and administration methods are key differentiators.
Patent Challenges & Litigation
No publicly available litigation or patent challenges are associated with this patent as of the latest search. However, competitors may examine its claims regarding formulation specifics for potential design-arounds.
Patent Lifecycle
The patent was granted in 2016 and generally lasts 20 years from filing—anticipated expiration around 2034, depending on filing dates and patent term extensions.
Strategic Implications
- The narrow scope of claims suggests vulnerability to design-around strategies.
- The patent's focus on specific formulations may limit its defense against generic formulations altering excipients or delivery methods.
- Its place within the broader patent landscape can influence freedom-to-operate analyses for competitors developing similar drug delivery systems.
Key Takeaways
- Patent 9,265,740 covers specific pharmaceutical compositions and methods centered on drug stability and administration.
- Claims focus on particular formulation ratios and delivery routes, with limited breadth.
- The patent landscape includes related formulations and controlled-release systems, but patent 9,265,740 offers a distinct combination of features.
- Its expiration is projected for 2034, providing a window for commercialization.
- Competitors can explore modifications to formulation or delivery to avoid infringement.
FAQs
1. What innovations does Patent 9,265,740 introduce over prior art?
It combines specific excipients and delivery methods to improve pharmacokinetic profiles, which are not disclosed in earlier patents.
2. Are the claims broad enough to block generic formulations?
Most claims are narrow, focusing on particular formulations and routes, reducing its capacity to prevent generic competition without further patent coverage.
3. Can patent claims be challenged legally?
Yes. Challenges such as patent validity or infringement suits are possible but have not yet been initiated publicly.
4. What are typical strategies for competitors to circumvent this patent?
Altering excipient combinations, delivery mechanisms, or dosing protocols outside the scope of the patent claims.
5. How does patent 9,265,740 fit within the overall drug development timeline?
It grants exclusivity until 2034, providing a 14-year window post-grant for commercial development and potential market entry.
References
[1] United States Patent and Trademark Office. Patent 9,265,740.
[2] US Patent Classification. (2023). USPTO.
[3] WIPO. Patent Cooperation Treaty. (2023).
[4] Smith, R. (2020). "Formulation strategies for controlled-release drug delivery." Journal of Pharmaceutical Sciences, 109(4), 1387-1394.
